Toggle light / dark theme

Chinese bitcoin miners have long dominated the global processing power that runs the bitcoin network with sophisticated equipment and access to cheap electricity. But now, a group of U.S. miners with deep pockets wants to conquer a greater share of the industry. Photo illustration: Clément Bürge.

More from the Wall Street Journal:
Visit WSJ.com: http://www.wsj.com.
Visit the WSJ Video Center: https://wsj.com/video.

On Facebook: https://www.facebook.com/pg/wsj/videos/
On Twitter: https://twitter.com/WSJ
On Snapchat: https://on.wsj.com/2ratjSM

#WSJ #Bitcoin #Crypto

Elon Musk’s SpaceX is preparing to further expand testing of its Starlink satellite internet in a test for the U.S. Air Force, an FCC request revealed.


Elon Musk’s SpaceX is preparing to further test its Starlink satellite internet in a demonstration for the U.S. Air Force, the company revealed in a recent request to the Federal Communications Commission.

“SpaceX seeks to make minor modifications to its experimental authorization for additional test activities undertaken with the federal government,” the company wrote to the FCC in a filing on Thursday.

“The tests are designed to demonstrate the ability to transmit to and receive information from two stationary ground sites and one airborne aircraft at one location, and would add to these limited testing from a moving vehicle on the ground,” SpaceX said.

The new treatment utilizes “artificial brainwaves” through a wearable device that according to clinical trials, resulted in 77% of subjects recovering faster from strokes if compared to those not using the treatment. The “artificial brainwaves” are delivered via electromagnetic radiation, which stimulates the nervous system to regrow and heal itself. In using this method, BrainQ was able to imitate the processes of neural network synchronization.

In a study conducted by the company, using a double-blind randomized controlled trial, it was found that after eight weeks of treatment, 77% of test subjects receiving BrainQ’s therapy had scores of 1 or 0 on the modified rankin scale, which indicates that either no symptoms or minor symptoms resulted from the trial, along with no significant disability.

The results of the study is expected to be presented at the International Stroke Conference in late March.